Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

d Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Media Contact:
     Dan Eramian
     T: 206.272.4343
     C: 206.854.1200
     E: media@ctiseattle.com
    http://www.CellTherapeutics.com/press_room

     Investors Contact:
     Ed Bell
     T: 206.272.4345
     Lindsey Jesch Logan
     T : 206.272.4347
     F : 206.272.4434
     E: invest@ctiseattle.com
    http://www.CellTherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
(Date:5/20/2013)... 2013   , ... ministers gather to address the large physical and economic ... disorders (MNDs) affect 700 million people annually and account ... ,Do You Mind?, helps patients, family members, ... play to collectively address MNDs , Today ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2
... ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 ... of an agreement to provide extended bioinformatics genomics services ... at Ambry. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO ... team at Ambry has been providing genomics solutions on ...
... , DOYLESTOWN, Pa., ... Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced ... opportunities to develop prescription pharmaceutical and OTC products and has ... primarily on the OTC/Personal Care marketplace, which may include but ...
Cached Medicine Technology:Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Long-acting ... chronic obstructive pulmonary disease (COPD) may raise the ... new large Canadian study reveals. The finding ... prescribed long-acting bronchodilators -- either anticholinergics (such as ... are commonly used to relieve the shortness of ...
(Date:5/21/2013)... News) -- Racial disparities exist in the treatment of ... States, according to a large new study. Although ... of their initial treatment, researchers found that blacks were ... in the early stages of the disease. Hispanics were ... stage 2 disease than white patients. "In our ...
(Date:5/21/2013)... ─ The negative effects of poorly controlled asthma ... urban schoolchildren has been confirmed in a new ... that missed sleep and school absences are important ... is the first to explore the associations between ... time, prospectively, using both objective and subjective ...
(Date:5/21/2013)... approach to obstructing the runaway inflammatory response implicated ... in a Phase IIa clinical trial, according to ... presented at the American Thoracic Society 2013 International ... New England Journal of Medicine . , The ... safety of the monoclonal antibody, dupilumab, in patients ...
(Date:5/21/2013)... Goderich, Ontario, CA (PRWEB) May 21, 2013 ... the fitness boot camp business Fit Body Boot ... Meltdown Challenge starting June 3rd at its Goderich fitness ... Fit Body Boot Camp’s 1,000 lb. Meltdown Challenge’s goal is ... total of 1,000 pounds in 28 days. The fee ...
Breaking Medicine News(10 mins):Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2Health News:Asthma symptoms impair sleep quality and school performance in children 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... 11 Wound Management,Technologies, Inc., (OTC Bulletin Board: ... potential acquisition of BioPharma Management Technologies, Inc.,a company ... pain,management products. "While we have been focusing ... products, we also have been working,to expand our ...
... Dec. 11 Barr Pharmaceuticals, Inc. (NYSE: ... Food and Drug Administration (FDA) has accepted for ... 7 Live Oral Vaccines Biologics License Application (BLA). ... development initiative and demonstrate the Company,s ability to ...
... research is declining sharply, more than 9 percent a year since ... of Pain . Pain research, as a result, now accounts ... Institutes of Health (NIH), despite the high prevalence of chronic pain ... government,s meager investment in pain research is seriously out of proportion ...
... are asking if cardiology patients receive intervention-type treatments, such as ... , In regions of the country where ... problems, patients may be receiving a treatment known as percutaneous ... to a study published online this week in the journal ...
... funding source to public health , ... Prevention today unveiled health reform recommendations to Congress that ... tackle the chronic diseases that are causing medical costs ... Under these proposals, federally funded insurance programs would provide ...
... CITY, Dec. 11 Genomma Lab Internacional,S.A.B. de ... a leading Mexican,over-the-counter ("OTC") pharmaceuticals and personal care ... personal hair care product line,Ma Evans. The ... campaign under,the brand name "Ma Evans Evolution". ...
Cached Medicine News:Health News:Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc. 2Health News:Wound Management Technologies, Inc. Announces Negotiations to Acquire BioPharma Management Technologies, Inc. 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 2Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 3Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 4Health News:Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA 5Health News:Study shows major pain research funding decline at NIH 2Health News:Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment? 2Health News:Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment? 3Health News:Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment? 4Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Genomma Lab Announces the Successful Launch of the Ma Evans Brand 2
... Array systems are fully automated ... fast turnaround of highly accurate ... drug monitoring (TDM) results. Using ... the easy-to-use Array® 360 performs ...
ELISA kit for detection of Rheumatoid Factor....
... create tired, dry eyes. With ACUVUE OASYS IN, ... challenging environments can make your eyes feel tired ... a computer can leave your eyes craving moisture. ... PLUS Brand Contact Lenses. It will almost ...
... Better. Introducing Disposable Bimanuals. With the ... need for quality single-use bimanuals. Oasis meets ... NEW disposable bimanuals. Single use bimanuals decrease ... time, they encompass all the advantages of ...
Medicine Products: